Literature DB >> 213191

Detection and significance of occult axillary node metastases in patients with invasive breast cancer.

E R Fisher, S Swamidoss, C H Lee, H Rockette, C Redmond, B Fisher.   

Abstract

Blocks of axillary lymph nodes from 78 patients with invasive breast cancer, which after "routine" pathological examination were regarded as negative for metastases, were step-sectioned at 20 u intervals. Occult metastases were detected in 24% of the cases. A significant association between such metastases and a lack of or slight degree of an intraductal carcinomatous component of the dominant cancer was noted. There was no relationship between occult metastases and 15 other histopathological and 3 clinical features investigated, including an average 5 year survival rate. Similarly there was no correlation between any of the possible discriminants investigated in the 24% of patients who have died of their diseases or are living with recurrence regardless of the presence of occult metastases. Factors accounting for the lack of universal survival in patients with Stage I (and those with occult metastases that might be designated as stage 11/2) remain enigmatic. It is concluded that attempts to detect occult metastases by extending histopathological methods may be more academic than practical or therapeutically significant.

Entities:  

Mesh:

Year:  1978        PMID: 213191     DOI: 10.1002/1097-0142(197810)42:4<2025::aid-cncr2820420452>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

Review 1.  Axillary staging of breast cancer and the sentinel node.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

Review 2.  [Lymph node dissection in patients with renal cell carcinoma].

Authors:  T Ebert; D Schnell; L Weissbach
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

3.  A multivariate study of the relationship between regional lymph node metastases and prognosis in patients with operable breast cancer.

Authors:  M Noguchi; T Taniya; N Koyasaki; N Ohta; I Miyazaki
Journal:  Jpn J Surg       Date:  1991-11

4.  Detection of axillary lymph node metastases in breast carcinoma by technetium-99m sestamibi breast scintigraphy, ultrasound and conventional mammography.

Authors:  W W Lam; W T Yang; Y L Chan; I E Stewart; C Metreweli; W King
Journal:  Eur J Nucl Med       Date:  1996-05

5.  Intraoperative assessment of axillary lymph node metastases in operable breast cancer.

Authors:  M Noguchi; M Minami; M Earashi; T Taniya; I Miyazaki; Y Mizukami; A Nonomura
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  What constitutes adequate study of axillary lymph nodes in breast cancer?

Authors:  W B Kingsley; G N Peters; J H Cheek
Journal:  Ann Surg       Date:  1985-03       Impact factor: 12.969

7.  Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients.

Authors:  Elizabeth A Mittendorf; Aysegul A Sahin; Susan L Tucker; Funda Meric-Bernstam; Min Yi; Khazi M Nayeemuddin; Gildy V Babiera; Merrick I Ross; Barry W Feig; Henry M Kuerer; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2008-09-25       Impact factor: 5.344

8.  Micrometastases from squamous cell carcinoma in neck dissection specimens.

Authors:  M W van den Brekel; H V Stel; P van der Valk; I van der Waal; C J Meyer; G B Snow
Journal:  Eur Arch Otorhinolaryngol       Date:  1992       Impact factor: 2.503

9.  Larger axillary metastases in obese women and smokers with breast cancer--an influence by host factors on early tumor behavior.

Authors:  H W Daniell; E Tam; A Filice
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Occult lymph node metastasis in gastric cancer with submucosal invasion.

Authors:  S Natsugoe; T Aikou; M Shimada; H Yoshinaka; S Takao; H Shimazu; Y Matsushita
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.